Up to 50% of women experience significant hair loss by age 50. The workup matters — secondary causes are common and treatable.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine • May 2026
Female hair loss is underdiagnosed, often dismissed, and frequently undertreated. It affects up to 50% of women by age 50 and carries significant quality-of-life impact. Here is the clinical framework for evaluation and treatment.
Female pattern hair loss (FPHL) is the most common cause of hair loss in women, but it is a diagnosis of exclusion. Before treating for FPHL, secondary causes must be ruled out:
FPHL is characterized by diffuse thinning over the central scalp with preservation of the frontal hairline — unlike the receding temporal hairline seen in male-pattern loss. The Ludwig scale grades severity:
Most patients present at Ludwig I or II, where treatment is most effective.
Before attributing hair loss to FPHL, check:
Correcting thyroid dysfunction or iron deficiency often substantially improves or resolves hair loss without any direct hair treatment.
Minoxidil (topical): FDA-approved for women at 2% concentration; 5% is more effective but not specifically approved for women (though widely used off-label and well-tolerated). Mechanism: vasodilation and potassium channel opening at the hair follicle, prolonging the anagen (growth) phase. Works in approximately 60-70% of women when used consistently. Must be used indefinitely — hair lost before treatment is not recoverable, and gains are lost when minoxidil is stopped. Side effects: scalp irritation, rarely unwanted facial hair growth at the 5% concentration.
Oral minoxidil: Low-dose oral minoxidil (0.25–1.25 mg daily) is increasingly used off-label for FPHL with good efficacy data and a better tolerability profile than topical for some patients. Lower doses minimize systemic side effects (fluid retention, hypertrichosis). Requires blood pressure monitoring.
Spironolactone: An aldosterone antagonist with anti-androgenic properties. Off-label for FPHL, particularly in women with evidence of androgen excess or who have not responded to minoxidil alone. Typical dose: 50–200 mg daily. Most effective in premenopausal women with elevated androgens. Requires potassium monitoring; not safe in pregnancy (teratogenic).
Finasteride: A 5-alpha reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). FDA-approved for men; used off-label in postmenopausal women. Not used in premenopausal women due to teratogenic risk (causes feminization of male fetuses). Evidence in postmenopausal women is positive with doses of 1–2.5 mg daily.
Platelet-rich plasma (PRP): In-office injections of concentrated platelets into the scalp. Evidence is moderately positive but inconsistent across trials. Best used as adjunct to medical therapy, not monotherapy.
Hair loss treatment is a marathon, not a sprint. The realistic timeline:
The goal for most patients is stabilization (stopping further loss) plus partial regrowth. Complete restoration to pre-loss density is rarely achievable through medical treatment alone.
For FPHL, minoxidil (topical or oral) has the strongest evidence base and is first-line. Spironolactone is effective for women with androgen excess. Finasteride is an option for postmenopausal women. Most women with significant FPHL benefit from combination therapy.
Secondary causes (thyroid, iron deficiency, postpartum) often fully reverse when the underlying cause is corrected. FPHL can be stabilized and partially reversed with treatment, but complete restoration to pre-loss density is rarely achieved through medical means alone.
TSH and ferritin are the highest-yield tests. Ferritin specifically (not just a CBC) because hemoglobin can be normal with iron deficiency sufficient to cause hair loss. Add androgens (testosterone, DHEA-S) if there are signs of androgen excess.
Finasteride is used off-label in postmenopausal women with good evidence at 1-2.5 mg daily. It is not used in premenopausal women due to teratogenic risk (it causes feminization of male fetuses and is category X in pregnancy).
This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed physician before starting any medication.
No credit card required. Live MD consult included.